Frazier Lifesciences Acquisition Q2 FY22: net loss $1.2M

Key figures from this report

These are the numbers Frazier Lifesciences Acquisition reported for Q2 FY22, the quarter ended Jun 30, 2022, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Net income−$1.2MAgainst −$1.3M in Q2 FY2110-Q income statement, on EDGAR
2. Cash and cash equivalents$615K−22% from $789K in Q2 FY2110-Q balance sheet, on EDGAR
3. Cash from operations−$173KAgainst −$778K in Q2 FY2110-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters